Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis
{{output}}
Introduction: Risankizumab (RZB) is an approved injectable IL-23 inhibitor with demonstrated high levels of skin clearance, and icotrokinra (ICO) is an oral IL-23 receptor blocker recently approved for the treatment of moderate-t... ...
